الفهرس 
coverOnly 14 pages are availabe for public view
 |  | from | 200 |  |  |
| | | from | 200 | | |
Abstract
Polycystic Ovarian Syndrome (PCOS) is one of the most common endocrine disorders of uncertain etiology, which affect between 6%-10% of women at reproductive age. It is characterized by menstrual abnormalities, hirsutism, acne anovulatory infertility, and elevated androgens. It has been confirmed that insulin resistance is a common feature in either obese or non obese women with PCOS. Elevated serum levels of interleukin-18 are associated with insulin resistance in women with polycystic ovary syndrome. (Tsilchoro Zidau et al., 2006).
Insulin sensitizing agents have recently been proposed as a therapy for the treatment of polycystic ovarian syndrome. These agents improve insulin action by increasing insulin sensitivity, thereby decrease hyperinsulinemia. The use of insulin sensitizers could therefore be suggested in most patients with PCOS. R/Metformine is the oldest and still the most used insulin sensitizer world wide in treatment of glucose intolerance, particularly type II diabetes Mellitus (Pasquali et al., 2000).